Source : Medtech Insight
The US government’s Biomedical Advanced Research and Development Authority (BARDA) has awarded Sonica Health more than $650,000 to help develop a wearable device that can detect SARS-CoV-2 infection, especially in high-risk individuals, before the user has noticeable symptoms of COVID-19, the agency announced on 1 July.
Sonica is a spinout of Northwestern University’s Querrey Simpson Institute for Bioelectronics in Evanston, IL. Led by John Rogers, a professor or materials science and engineering at Northwestern, the start-up has developed ADAM, a bio-integrated flexible patch that identifies early signs of a a SARS-CoV-2 infection in the lungs.
ADAM is a small patch about the size of a Band-Aid designed to be worn at the base of the throat. It monitors patients breathing pattern, heart rate, physical activity and temperature as well as coughing and other respiratory sounds that indicate the onset of COVID-19. It creates a continuous stream of wirelessly transmitted data that is analysed with signal-processing and machine-learning algorithms developed by researchers at Northwestern University in Evanston, IL, and the Shirley Ryan AbilityLab in Chicago. ADAM will also feature the ANNETM one sensor system, developed by fellow Northwestern spin-off Sibel Health, to monitor pulse oximetry and electrocardiography data.
BARDA is part of the US Department of Health and Human Services, overseen by HHS' Office of the Assistant Secretary for Preparedness and Response. The award to Sonica is part of BARDA’s effort to develop a “COVID-19 medical countermeasure portfolio” of promising diagnostics, devices and drugs that may help combat COVID-19.
In June, BARDA awarded about $718,009 to Empatica, Inc. to develop the E4 wristband device that can detect early signs of SARS-CoV-2 infection in based on physiologic signals.
BARDA also recently awarded nearly $630,000 to MBio Diagnostics Inc.. to help develop a point-of-care COVID-19 antibody diagnostic panel that will be able to simultaneously measure the levels of the SARS-CoV-2 antibodies and antigens in blood plasma samples from patients who have recovered from COVID-19.
Other diagnostic companies receiving BARDA grants to help develop COVID-19 diagnostics include Nanomix Inc., Mesa Biotech, Hologic Inc., DiaSorin SPA, Cepheid, Luminex Corp. and Qiagen NV. ("COVID19 Nanomix Wins BARDA Funding For Mobile PointOfCare Assay" "Medtech Insight" )
By Reed Miller